Evidence map›Paper›PMID 40205351›Full record

ArticleBMC cancer2025

Role of MRE11 in DNA damage repair pathway dynamics and its diagnostic and prognostic significance in hereditary breast and ovarian cancer.

Bhoomi Tarapara, Franky Shah

Abstract read
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Bhoomi TaraparaDepartment of Life-Science, Gujarat University and Young Scientist (DHR-ICMR), Molecular Diagnostic & Research Lab-3, Department of Cancer Biology, The Gujarat Cancer & Research Institute, Ahmedabad, Gujarat, 380016, India.ORCID http://orcid.org/0000-0001-9262-925X
Franky ShahDepartment of Cancer Biology, Molecular Diagnostic & Research Lab- 3, The Gujarat Cancer & Research Institute, Ahmedabad, Gujarat, 380016, India. franky.shah@gcriindia.org.ORCID http://orcid.org/0000-0002-7265-2839

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDNA damage repair pathway genes are key components for maintaining genomic stability and are mainly associated with hereditary breast and ovarian cancer.

methodsThe present study aimed to investigate the gene expression profile of DNA damage repair pathway genes, including BRCA1, BRCA2, ATM, TP53, CHEK2, MRE11, RAD50, BARD1, PALB2, and NBN, in hereditary breast and ovarian cancer patients using quantitative real-time PCR.

resultsThe study showed significant upregulation of most DNA damage repair genes in HBOC patients compared to controls, except MRE11, which was downregulated. Receiver operating characteristic (ROC) curve analysis revealed that MRE11 (p < 0.001), BRCA1 (p < 0.001), BRCA2 (p < 0.001), and PALB2 (p < 0.001) can be used as potential diagnostic biomarkers for hereditary breast and ovarian cancer. Spearman correlation analysis showed that RAD50 was significantly associated with the BRCA1/2 mutation status (p = 0.05). Furthermore, bivariate analysis revealed a strong positive correlation between BARD1 gene expression and the expression of BRCA1, PALB2, and NBN genes. Kaplan-Meier survival analysis showed that reduces expression of the MRE11 gene was associated with better overall survival.

conclusionsThe study findings may lead to a better understanding of the molecular mechanisms underlying hereditary breast and ovarian cancer, suggesting its role as a potential diagnostic and prognostic marker.

Indexed as

DNA DamageDNA RepairHereditary Breast and Ovarian Cancer SyndromeMRE11 Homologue ProteinOvarian NeoplasmsAcid Anhydride HydrolasesAdultAgedBiomarkers, TumorBRCA1 ProteinBRCA2 ProteinDNA-Binding ProteinsDNA Repair EnzymesFanconi Anemia Complementation Group N ProteinFemaleGene Expression Regulation, NeoplasticAcid Anhydride HydrolasesBARD1 protein, humanBiomarkers, TumorBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanDNA-Binding ProteinsDNA Repair EnzymesFanconi Anemia Complementation Group N ProteinMRE11 Homologue ProteinMRE11 protein, humanPALB2 protein, humanRAD50 protein, humanTumor Suppressor ProteinsUbiquitin-Protein LigasesBRCA1BRCA2DNA damage repairHereditary breast and ovarian cancerPeripheral bloodReal time PCR

Identifiers

PMID40205351
PMCPMC11984277

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.